Marché Fermé -
Autres places de cotation
|
Pré-ouverture 08:51:49 | |||
88 EUR | -0,23 % | 87,92 | -0,10 % |
08:41 | CAC 40 : pas de grand chambardement après la BoJ | CF |
18/03 | AstraZeneca suit son rival Boehringer en plafonnant les frais à la charge du patient pour les inhalateurs | RE |
Métier
- produits pharmaceutiques (71,4%) : médicaments de prescription dans les domaines de la médecine de spécialité (54,7% du CA ; destinés au traitement du sclérose en plaques, des maladies neurologiques, des maladies inflammatoires, des maladies auto-immunes, des maladies rares, des cancers et des maladies hématologiques rares) et de la médecine générale (45,3% ; destinés essentiellement au traitement du diabète et des maladies cardiovasculaires) ;
- vaccins humains (16,8%) : vaccins pédiatriques, vaccins contre la grippe, la méningite et la poliomyélite, vaccins de rappel et vaccins destinés aux voyageurs et aux zones endémiques ;
- produits de santé grand public (11,8%).
A fin 2022, le groupe dispose de 59 sites de production dans le monde.
La répartition géographique du CA est la suivante : France (5,3%), Europe (18%), Etats-Unis (42,5%), Chine (7,3%), Japon (3,8%), Brésil (2,1%), Russie (1,5%) et autres (19,5%).
Nombre d'employés: 86 088
Ventes par activité
EUR en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Biopharma
88,0
%
| 30 688 | 71,4 % | 37 890 | 88,0 % | +23,47 % |
Consumer Healthcare
12,0
%
| 5 080 | 11,8 % | 5 180 | 12,0 % | +1,97 % |
Ventes par région
EUR en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
43,0
%
| 18 275 | 42,5 % | 18 512 | 43,0 % | +1,30 % |
Rest of the World
26,1
%
| 8 386 | 19,5 % | 11 254 | 26,1 % | +34,20 % |
Europe
18,6
%
| 7 703 | 17,9 % | 8 013 | 18,6 % | +4,02 % |
China
6,8
%
| 3 123 | 7,3 % | 2 912 | 6,8 % | -6,76 % |
France
5,5
%
| 2 296 | 5,3 % | 2 379 | 5,5 % | +3,61 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 01/09/19 |
Director of Finance/CFO | 59 | 01/10/18 | |
Nestle Frank
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/16 |
Madeleine Roach
COO | Chief Operating Officer | 39 | 01/01/22 |
Chief Tech/Sci/R&D Officer | 51 | - | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 49 | 11/09/23 |
Dietmar Berger
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/19 |
Arnaud Delépine
IRO | Public Communications Contact | - | - |
Investor Relations Contact | - | 01/07/20 | |
Natalie Bickford
HRO | Human Resources Officer | 53 | 01/08/20 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 01/05/14 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 22/05/20 |
Rachel Duan
BRD | Director/Board Member | 52 | 28/04/20 |
Director/Board Member | 61 | 03/05/13 | |
Thomas C. Südhof
BRD | Director/Board Member | 68 | 01/05/16 |
Antoine Yver
BRD | Director/Board Member | 66 | 03/05/22 |
Barbara Lavernos
BRD | Director/Board Member | 55 | 30/04/21 |
Diane D. Souza
BRD | Director/Board Member | 71 | 04/05/16 |
Yann Tran
BRD | Director/Board Member | 58 | 01/05/21 |
Wolfgang Laux
BRD | Director/Board Member | 56 | 01/04/21 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 1 264 799 969 | 1 110 144 426 ( 87,77 %) | 13 450 388 ( 1,063 %) | 87,77 % |
Participations
Nom | Actions | % | Valorisation |
---|---|---|---|
SANOFI INDIA LIMITED 60,40% | 13 909 587 | 60,40% | 1 445 172 845 $ |
SANOFI 0,96% | 12 195 470 | 0,96% | 1 159 913 103 $ |
EUROAPI 29,77% | 28 298 074 | 29,77% | 117 897 700 $ |
MEIRAGTX HOLDINGS PLC 7,39% | 4 697 737 | 7,39% | 28 985 037 $ |
LAVA THERAPEUTICS N.V. 7,30% | 1 919 455 | 7,30% | 6 391 785 $ |
CLOUDR GROUP LIMITED 0,66% | 3 860 600 | 0,66% | 2 633 315 $ |
ENENTO GROUP OYJ 0,12% | 29 249 | 0,12% | 546 310 $ |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Chattem, Inc.
Chattem, Inc. Pharmaceuticals: MajorHealth Technology Chattem, Inc. engages in the manufacture of over-the-counter health and beauty care products. It makes anti-dandruff shampoos, medicated skin care, topical pain care, oral care and internal over-the-counter products. The firm distributes its products to mass merchandisers, drugstores and food retail channels. The company was founded by Zeboim Cartter Patten on February 21, 1879 and is headquartered in Bridgewater, NJ. |
Pharmaceuticals: Major
|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. |
Medical Specialties
|
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Aventis, Inc.
| |
Sanofi-Synthélabo Ltd.
Sanofi-Synthélabo Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Synthélabo Ltd. is a pharmaceutical company based in Reading, UK. The British company was founded in 1990 and specializes in manufacturing and distributing solid-dose and pharmaceutical products. |
Pharmaceuticals: Major
|
Sanofi Pasteur, Inc.
Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. |
Pharmaceuticals: Major
|
Sanofi-aventis Ireland Ltd.
Sanofi-aventis Ireland Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-aventis Ireland Ltd. manufactures pharmaceutical products for cardiovascular, central nervous system, metabolic disorders, cardiometabolic, oncology, thrombosis, and vaccines. The company is headquartered in Dublin, Ireland. |
Pharmaceuticals: Major
|
Sanofi-Aventis Europe SAS
Sanofi-Aventis Europe SAS Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Aventis Europe SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the private company is Jérôme Contamine. |
Pharmaceuticals: Major
|
Genzyme Therapeutic Products LP
Genzyme Therapeutic Products LP BiotechnologyHealth Technology Part of Sanofi, Genzyme Therapeutic Products LP is a private company that specializes in biological products except diagnostic substances. The company is based in Boston, MA. |
Biotechnology
|
Secteur
Ventes par activité
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
-1,96 % | 119 Md | |
+30,83 % | 687 Md | |
+30,96 % | 595 Md | |
+0,01 % | 378 Md | |
+15,18 % | 316 Md | |
+11,39 % | 308 Md | |
+0,78 % | 211 Md | |
-6,09 % | 208 Md | |
-2,92 % | 203 Md | |
-3,72 % | 157 Md |
- Bourse
- Actions
- Action Sanofi - Euronext Paris
- Société Sanofi